Check 35,000+ stocks against 26 valuation models and 37 quality factors

Teva Pharmaceutical Industries Limited (TEVJF) fair value: what the stock is really worth

As of Sep 18, 2026: fair value of Teva Pharmaceutical Industries Limited $42.88, price $38.98, upside +10.0%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US8816242098

Broad data Oct 3, 2026

Teva Pharmaceutical Industries Limited

TEVJF · US

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value $42.88 · Fairly valued (+10.0%)

✓Quality 63/100

!Mixed Growth (revenue 5y +2.3 %/yr)

!Thin margins · 9.0% net margin (TTM)

!High debt · generates free cash flow

!Moderate moat 61/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $7.00 – $39.25 · fair‑value band $31.82 – $55.74 · the $38.98 price screens below the $42.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 3, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Stock analysis

Teva Pharmaceutical Industries Limited (TEVJF) currently trades at $38.98, while our model-based Fair Value estimate is $42.88, implying the stock looks roughly 9.1% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $32.83 per share, and 4 of the 24 models we run sit above the $38.98 price.

Bear case: the Asset-Based group reads lowest at $4.55, and 20 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $31.82 (bear) to $55.74 (bull), the price of $38.98 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Teva Pharmaceutical Industries Limited reported revenue of $18.7B in FY2025 versus $15.9B in FY2021, a compound +4.1%/yr. Reported net income was $1.5B in FY2025, compounding +38.3%/yr from FY2021.

Key figures

Market cap $45.3B · P/E ratio 29.1 · P/S ratio 2.38 · EPS (TTM) $1.34 · Net margin 8.2% · Return on equity 21.6% · Return on assets (EBIT) 3.0% · Operating margin 19.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 1% below its 52-week high and 172% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 10%, TEVJF screens cheaper than that median.

Fair Value models

Bear $31.82 Fair Value $42.88 Bull $55.74

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.01 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $26.31 $51.05 $91.52 77

Growth DCF $26.47 $50.24 $88.73 75

Owner Earnings $21.23 $42.50 $77.29 73

All 24 models by family

DCF Models

FCF DCF $26.31 $51.05 $91.52 77

Owner Earnings $21.23 $42.50 $77.29 73

5Y Revenue Exit $13.15 $25.58 $41.51 70

5Y EBITDA Exit $19.89 $38.87 $61.63 73

5Y P/E Exit $15.31 $29.85 $45.56 69

10Y Revenue Exit $16.87 $29.79 $47.63 65

10Y EBITDA Exit $21.80 $39.28 $63.75 66

10Y P/E Exit $18.82 $32.83 $50.87 62

Earnings-Based

Graham-Dodd $8.92 $34.89 $47.34 64

Lynch FV $8.59 $12.26 $15.94 61

PEG = 1.0 $8.59 $12.26 $15.94 57

EPV $6.06 $8.71 $11.02 73

Multiples

P/E Multiple $21.64 $28.86 $36.07 63

P/S Multiple $16.72 $22.30 $27.87 58

P/B Multiple $16.72 $22.30 $27.87 55

EV/EBIT $13.80 $21.68 $29.55 64

EV/EBITDA $19.42 $29.16 $38.90 66

EV/Revenue $7.04 $14.27 $21.49 51

Asset-Based

NCAV (Graham) $3.40 $4.55 $6.79 54

Growth DCF

Growth DCF $26.47 $50.24 $88.73 75

Rev-Margin DCF $13.15 $25.75 $41.29 70

Economic Profit

Residual Income $8.31 $11.00 $18.90 68

ROIC Compounder $6.06 $10.45 $17.12 69

Growth Earnings

Growth-Adj P/E $15.77 $22.53 $29.29 67

Open the full fair value analysis →

Notify me when TEVJF reaches fair value

Put TEVJF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 63/100

Of which business quality 57 · Market factors (momentum, volatility) 77

Profitability 44

Margins and returns on capital today

Quality Growth 83

Are margins and returns improving?

Cashflow 76

Earnings quality: real cash, not paper profit

Fin. Strength 12

Balance sheet, leverage, solvency risk

Investment 98

Disciplined investing over empire-building

Low Volatility 37

Calm price path (market factor)

Momentum 90

Price trend over the last 3–12 months (market factor)

52W Momentum 100

Distance to the 52-week high (market factor)

Net Issuance 60

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+12.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.3%

Start year 2020 (pandemic). Over 10 years: −0.5% a year

Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.2%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+28.4%

Earnings growth per share plus dividend.

Earnings per share, growth per year+28.4%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.28.4% vs −3.3%, picking up

Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 12%

Start year 2020 (pandemic)

⚠ Revenue per share shrinking 4.7%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+9.8%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+0.3%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +7.3% a year for the price and −2.0% for the forecasts.

Forecast 2026 (sales)−10.9%

Forecast 2027 (sales)+3.7%

Projected 2028 (sales)+3.5%

Projected 2029 (sales)+3.3%

Projected 2030 (sales)+3.0%

Watch TEVJF, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

Teva's Branded Drugs Take Center Stage in Its Growth Strategy Yahoo Finance · Sep 29, 2026
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) Yahoo Finance · Sep 28, 2026
Teva Releases Q3 2026 Aide Memoire Yahoo Finance · Sep 23, 2026
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET Yahoo Finance · Sep 23, 2026

Compare Teva Pharmaceutical Industries Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%
Hansoh Pharmaceutical Group 3692	HK$33.52	HK$36.87	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Teva Pharmaceutical Industries Limited · Fair Value
$42.88 +9%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/TEVJF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Teva Pharmaceutical Industries Limited · Fair Value</span><br><b style="font-size:20px">$42.88</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+9%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Teva Pharmaceutical Industries Limited Fair Value". https://www.fairvalue-calculator.com/stock/TEVJF

Frequently asked questions

Is Teva Pharmaceutical Industries Limited (TEVJF) overvalued or undervalued?

As of Oct 3, 2026, our model estimates a fair value of $42.88 versus the last price from Sep 18, 2026 of $38.98, about +10% upside (undervalued).

What is the fair value of TEVJF?

Our model-based fair value for Teva Pharmaceutical Industries Limited is $42.88 (as of Oct 3, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $38.98.

What is the quality score of TEVJF?

Teva Pharmaceutical Industries Limited has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Teva Pharmaceutical Industries Limited (TEVJF)?

Our model-based price target is the fair value of $42.88 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario $31.82, optimistic scenario $55.74. It is a calculation from audited fundamentals, not an analyst target.

What is the Teva Pharmaceutical Industries Limited stock forecast for 2026?

Our models put fair value at $42.88, about +10% upside versus the last price from Sep 18, 2026 of $38.98 (undervalued). Cautious scenario $31.82, optimistic scenario $55.74. The calculation is refreshed regularly with new filings.

What is the revenue of Teva Pharmaceutical Industries Limited (TEVJF)?

Teva Pharmaceutical Industries Limited reported trailing-twelve-month revenue of about $17.3B (latest available figure, as of Oct 3, 2026).

What growth is priced into Teva Pharmaceutical Industries Limited (TEVJF)?

For today's price to be fair in a discounted-cash-flow model, Teva Pharmaceutical Industries Limited would have to grow free cash flow by +9.8 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.3 % per year. As of Oct 3, 2026.

What discount rate (WACC) does the fair value of TEVJF use?

Our models discount Teva Pharmaceutical Industries Limited at 8.9 %: a base by market capitalisation (large), damped by beta 0.85, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Teva Pharmaceutical Industries Limited that is +9.8 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.

How much growth has Teva Pharmaceutical Industries Limited (TEVJF) delivered so far?

Over the past 5 years revenue at Teva Pharmaceutical Industries Limited grew +2.3 % a year. The price currently implies +9.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Teva Pharmaceutical Industries Limited (TEVJF) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Teva Pharmaceutical Industries Limited (+9.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Teva Pharmaceutical Industries Limited (TEVJF)?

The free-cash-flow yield on the price is 5.64 %: that much free cash flow Teva Pharmaceutical Industries Limited produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Teva Pharmaceutical Industries Limited (TEVJF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Teva Pharmaceutical Industries Limited it is $42.88 per share (as of Oct 3, 2026), against a price of $38.98. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Teva Pharmaceutical Industries Limited stock overvalued or undervalued in 2026?

As of Oct 3, 2026, TEVJF trades below its calculated fair value: price $38.98, fair value $42.88, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of TEVJF?

No. The price is what the market pays today ($38.98); the fair value is what the company's own numbers justify ($42.88). For Teva Pharmaceutical Industries Limited the two are $3.90 per share apart. That gap is exactly why we show both numbers side by side.

How much is Teva Pharmaceutical Industries Limited worth?

The market values Teva Pharmaceutical Industries Limited at about $45.3B (market capitalisation, as of Oct 3, 2026). Per share that is $38.98; our models calculate a fair value of $42.88 per share.

What do the bullish and bearish scenarios say about TEVJF?

Our models span a range for Teva Pharmaceutical Industries Limited: cautious scenario $31.82, base $42.88, optimistic $55.74 per share (as of Oct 3, 2026, price $38.98). The range comes from different growth and margin assumptions, not from analyst opinions.

How far is TEVJF from its 52-week high?

Teva Pharmaceutical Industries Limited trades at $38.98, about 1% below its 52-week high of $39.25 and 172% above the low of $14.32 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $42.88 is for.

Which stocks are comparable to Teva Pharmaceutical Industries Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Teva Pharmaceutical Industries Limited stock attractive at the current price?

The data as of Oct 3, 2026: price $38.98, calculated fair value $42.88 (+10%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of TEVJF calculated?

We run Teva Pharmaceutical Industries Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $42.88, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Teva Pharmaceutical Industries Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Teva Pharmaceutical Industries Limited (TEVJF)?

The latest price we hold is from Sep 18, 2026 and stands at $38.98. Our model-based fair value is $42.88, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Teva Pharmaceutical Industries Limited right now?

The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Teva Pharmaceutical Industries Limited

How large is the market capitalisation of Teva Pharmaceutical Industries Limited (TEVJF)?

The market capitalisation of Teva Pharmaceutical Industries Limited is $45.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/E ratio of Teva Pharmaceutical Industries Limited (TEVJF)?

The price-to-earnings ratio of Teva Pharmaceutical Industries Limited is 29.1. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.

What is the P/S ratio of Teva Pharmaceutical Industries Limited (TEVJF)?

The price-to-sales ratio of Teva Pharmaceutical Industries Limited is 2.38 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Teva Pharmaceutical Industries Limited (TEVJF)?

Earnings per share at Teva Pharmaceutical Industries Limited are $1.34 (price ÷ EPS = P/E 29.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Teva Pharmaceutical Industries Limited (TEVJF)?

The net margin of Teva Pharmaceutical Industries Limited is 8.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Teva Pharmaceutical Industries Limited (TEVJF)?

The return on equity (ROE) of Teva Pharmaceutical Industries Limited is 21.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Teva Pharmaceutical Industries Limited (TEVJF)?

On an EBIT basis the return on assets of Teva Pharmaceutical Industries Limited is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Teva Pharmaceutical Industries Limited (TEVJF)?

The operating margin of Teva Pharmaceutical Industries Limited is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Teva Pharmaceutical Industries Limited (TEVJF)?

Revenue at Teva Pharmaceutical Industries Limited is growing +2.3% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Teva Pharmaceutical Industries Limited (TEVJF)?

Earnings per share at Teva Pharmaceutical Industries Limited are growing +72.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Teva Pharmaceutical Industries Limited (TEVJF) carry?

The net debt of Teva Pharmaceutical Industries Limited is $13.5B (fiscal year 2025, ≈ 5.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.